BDDS
Technology platformA brain-targeted polymer-based delivery platform, the subject of a joint research and option agreement worth up to USD 861 million with a global drugmaker in March 2023.
FROM PUBLIC EVENTS · 2026-11-18
Discovery · preclinical Continuing brain-targeted RNA candidate discovery through a national drug development project and a university partnership.
Roles often seen at this stageResearch & development · Data & AI · BD & licensing
A developer of RNA medicines for neurological and rare diseases that owns the brain-targeted delivery platform BDDS and the candidate BMD-001.
A brain-targeted polymer-based delivery platform, the subject of a joint research and option agreement worth up to USD 861 million with a global drugmaker in March 2023.
A brain-disease drug candidate pairing an RNA molecule with the BDDS platform.
Selected to carry out a hit-stage discovery project in the second 2026 round of the Korea Drug Development Fund program.
Signed an agreement with Soonchunhyang University's AIBIOME program on AI-based biopharmaceutical research and talent training.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.